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Abstract
Background: XMRV is the most recently described retrovirus to be found in Man, firstly in patients with prostate cancer (PC)
and secondly in 67% of patients with chronic fatigue syndrome (CFS) and 3.7% of controls. Both disease associations remain
contentious. Indeed, a recent publication has concluded that ‘‘XMRV is unlikely to be a human pathogen’’. Subsequently
related but different polytropic MLV (pMLV) sequences were also reported from the blood of 86.5% of patients with CFS.
and 6.8% of controls. Consequently we decided to investigate blood donors for evidence of XMRV/pMLV.
Methodology/Principal Findings: Testing of cDNA prepared from the whole blood of 80 random blood donors, generated
gag PCR signals from two samples (7C and 9C). These had previously tested negative for XMRV by two other PCR based
techniques. To test whether the PCR mix was the source of these sequences 88 replicates of water were amplified using
Invitrogen Platinum Taq (IPT) and Applied Biosystems Taq Gold LD (ABTG). Four gag sequences (2D, 3F, 7H, 12C) were
generated with the IPT, a further sequence (12D) by ABTG re-amplification of an IPT first round product. Sequence
comparisons revealed remarkable similarities between these sequences, endogeous MLVs and the pMLV sequences
reported in patients with CFS.
Conclusions/Significance: Methodologies for the detection of viruses highly homologous to endogenous murine viruses
require special caution as the very reagents used in the detection process can be a source of contamination and at a level
where it is not immediately apparent. It is suggested that such contamination is likely to explain the apparent presence of
pMLV in CFS.
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Introduction
A novel retrovirus, xenotropic murine leukaemia virus-related
virus (XMRV), probably of mouse origin, was identified in nucleic
acid (NA) extracted from human prostate cancers using a multi-virus
array [1]. Initial USstudies indicated a high prevalence of infection in
patients with prostate cancer (PC) suggesting a possible aetiologic link
[1], although this remains unproven. Intravenous inoculation of
macaques with XMRV caused infection with a short plasma and
cellular viraemia followed by subsequent seroconversion [2].
Late in 2009 Lombardi and colleagues reported the presence of
XMRV DNA in peripheral blood leucocytes from 67% of patients
with chronic fatigue syndrome (CFS) and 3.7% of healthy controls
[3]. They subsequently amended the prevalence to 7% as
measured by PCR of genomic DNA and stated that cDNA
synthesis was required to achieve the 67% prevalence [4]. In
addition the original study reported the isolation of XMRV from
patients with CFS from both peripheral blood leucocytes and from
plasma. Lo and colleagues using predominantly archival material
from patients with CFS detected a high prevalence (86.5%) of
pMLVs similar to, but different from, XMRV [5]. Other studies
failed to demonstrate a link between XMRV infections and CFS
[6,7,8,9,10]. Studies of XMRV infection in patients with PC
indicate that XMRV is rarely present in prostatic cancer tissues
and that antibody to XMRV cannot be detected reliably in the
plasma of patients with PC [1,11,12,13,14,15]. It has been
suggested that the failure to detect XMRV NA in such patients is
due to the use of DNA detection protocols rather than those
targeting RNA [4,16]
While developing a sensitive and robust detection protocol for
viral RNA in blood samples we encountered what appeared to be
contamination of PCR reagents. We examined one potential
source of contaminating murine retroviral sequences using
protocols derived from Urisman [1], Lombardi [3] and Lo [5]
and their colleagues.
Materials and Methods
Whole blood samples were obtained from Donation Testing at
the National Health Service Blood and Transplant (NHSBT)
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from 273 ml of whole blood on a Qiagen MDx Bio-robot and
eluted into 80 ml of AVE buffer. Nuclease-free water (Severn
Biotech) was used throughout for the cDNA and PCR mix
preparations and as no template controls. cDNA synthesis was
undertaken on 80 NA extracts that did not contain detectable gag
XMRV proviral sequences as determined using a previously
described TaqMan assay [17] but performed using reagents as
detailed in Table 1. A total volume of 20 ml contained 16 IPT
PCR buffer, 0.5 mM each dNTP, 5 mM MgCl2, 6.7 ng/ml
random hexamers (Invitrogen), 6.8 U RNAsin (Promega), 100 U
MMLV RT (Invitrogen). Synthesis conditions were 37uC for
90 mins, 95uC for 5 mins.
A modified XMRV gag TaqMan assay, using probe P2 and
primers F3 and R4, redesigned to co-detect the pMLVs described
by Lo and colleagues, was also used to analyse the cDNAs. The
assay conditions were as previously described [17] however, the
Qiagen Quantitect PCR probe mix was used. Details of this and
subsequent PCR reactions are listed in Table 1.
P2 59-Fam-CCG ACA GCT CCC GTC CTC CCG-
Tamra-39
F3 59-ACC GTT TGT CTC TCC TAA AC-39
R4 59-AGG GTA AAG GGC AGA TCG-39
To detect murine genomic DNA sequences a TaqMan assay to
the LTR sequence of a reconstructed ancestral intra-cisternal A
type particle (IAP) sequence [18] was designed using Beacon
Designer 7.9 software (Premier Biosoft). It was able to detect
0.01 pg of Balb/c DNA. The probe and primer sequences were:
IAPE D1 Probe 59-Cy5-CGT CCG TCT GAT CGT GCT
TC BHQ3-39
IAPE D1 F 59-CTG TGT TAA CCC TAT TTC TC-39
IAPE D1 R 59-GAG AGG CTT AAA TAT GAG AC-39
IAP LTR sequences were sought at the same time as XMRV/
pMLV in the IPT reagents by TaqMan PCR under the following
conditions: Total volume of 25 ml containing 16IPT PCR buffer,
0.2 mM each dNTP, 2.5 mM MgCl2, 0.625 U of Platinum Taq
DNA Polymerase (Invitrogen) and ROX was added to the PCR
master mix as specified by the manufacturer of the QPCR
machine.
PCR products were purified and sequenced. Sequences 1F,
1F_131010, 2D, 3F, 7C, 7H, 9C, 12C and 12D are deposited with
GenBank, with the following respective GenBank accession
numbers JF491136, JF491128, JF491134, JF491135, JF491129,
JF491132, JF491130, JF491131 and JF491133. Sequence homol-
ogy searches were performed using the EBI server and FASTA
programme. To examine the relationship between our sequences
and other MLVs, we aligned them to a collection of endogenous
MLVs [19], XMRV VP62 [1], the sequences described by Lo and
colleagues [5] and subsequent database submission (HQ601957–
HQ601962) using MegAlign (DNAstar) or MUSCLE [X].
RAxML [Y] (GTR model [Z], Gamma-distributed rates) was
used to create the tree topology and optimise the branch lengths.
Bootstrap values were estimated from 200 replicates. Branches
with less than 50% support were collapsed.
Results
In initial experiments designed to test methodology for
screening the blood supply, we examined 80 cDNAs from normal
blood donors using the modified XMRV gag TaqMan protocol.
None contained detectable XMRV/pMLV sequences. Subse-
quently, in experiment 1 (Table 2) gag amplification using IPT was
performed on these same 80 cDNAs, essentially as previously
described by Urisman [1], Lombardi [3] and Lo [5]. Two samples,
7C and 9C, gave visible bands of apparently the anticipated size
(413 bp) in round two (R2) (Fig. 1). 7C also gave a visible band of
the anticipated size (c 730 bp), in round one (R1). When the IPT
reagents were substituted with ABTG reagents in a second set of
experiments, re-amplification of 8 cDNAs, including 7C and 9C,
using the nested gag primers failed to generate any detectable
products. Using the pol nested PCR primers described by Switzer
and colleagues [20] (Table 1) to re-amplify 8 cDNAs, including 7C
and 9C, the cDNA of 9C failed to amplify and only 7C amplified a
visible product in R2 (Experiment 3, Table 2).
7C was a modified polytropic murine retrovirus (mpMLV) gag
sequence, related to (96.8% homology), but distinct from XMRV.
7C was most closely related (with 99.7% homology) to an
endogenous MLV (AC153369 10 BAC RP23-103E4). 7C was
essentially identical (99.7%) to 12C (obtained subsequently from
Table 1. Details of PCRs performed.
PCR Primers and probes Reagents Conditions
gag R1
gag R2
419F 1154R [3]
gagIF gagIR [1]
Invitrogen Platinum Taq 4 min at 94uC
(1 min 94uC, 1 min 57uC, 1 min 72uC)645
cycles and 10 min 72uC.
gag R1
gag R2
419F 1154R [3]
gagIF gagIR [1]
Applied Biosystems Taq Gold LD 10 min at 95uC
(1 min 95uC, 1 min 57uC, 1 min 72uC)645
cycles and 10 min 72uC.
XMRV Taq Man XMRV Probe, F, R [17] Qiagen Quanti Tect Probe kit 15 min at 95uC
(15 secs 95uC, 1 min 60uC)660 cycles.
XMRV/pMLV Taq Man P2, F3, R4 Qiagen Quanti Tect Probe kit 15 min at 95uC
(15 secs 95uC, 1 min 60uC)660 cycles.
XMRV/pMLV with IAPE Taq Man P2, F3, R4
IAPE D1Probe, D1F, D1R
Invitrogen Platinum Taq 4 min at 95uC
(15 secs 95uC, 1 min 72uC)660 cycles.
CDC pol XPOLOF XPOLOR [20] XPOLIF
XPOLIR [20]
Invitrogen Platinum Taq 4 min at 94uC
(30 secs 94uC, 30 secs 57uC, 1 min
72uC)645 cycles and 10 min 72uC.
400 nM concentrations of primers and 200 nM probes were used in all the TaqMan assays.
doi:10.1371/journal.pone.0019953.t001
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9C was a xenotropic virus sequence most closely related to XMRV
(98.7% homology) but with a 45-base pair deletion (Table 2). The
pol sequence from 7C had 100% homology with a MLV sequence
AC117614 (Table 2) and was highly similar to AF033811 Mo-
MLV (98.2% homology).
We next tested 88 replicates of no template (water) controls
using the nested gag primers and two enzyme systems (Experiment
2, Table 1). All 88 replicates of water control wells were unreactive
when amplified by ABTG. IPT produced four R2 visible products
(2D, 3F, 7H and 12C Fig. 1). 12 C was also visible in R1.
Sequencing confirmed high identity to a number of gag loci in the
mouse genome (Table 2). Re-amplification of the four R1 products
which generated a R2 signal and four adjacent ‘‘water controls’’
but using ABTG and gag IF IR only re-amplified the R1 positive
sample 12C with a sequence identical to that found previously.
One of four ‘‘water controls’’ (12D), previously unreactive gave an
amplicon 12 D which was identical to a murine endogenous gag
sequence CR954969 (Table 2).
Hence five different murine related retroviral sequences were
amplified in R2 from 88 waters but only where the R1 had been
generated with IPT. The further investigation of the R1 products
makes it most likely that excipient material within the Invitrogen
enzyme and master mix was the source of these sequences. In total
seven discrete MLV sequences were amplified, two in the cDNA
amplifications (Experiment 1) and five in the amplifications of the
water (Experiment 2). The water itself is not the source of these
sequences as all 88 were negative in the nested gag ABTG
amplifications. The sensitivity of the two amplification methods
were shown to be equivalent both on XMRV derived cDNA and
Balb/c DNA (data not shown).
The TaqMan Q-PCR set up using the IPT PCR reagents
multiplexed with the XMRV/pMLV with IAPE-D1 components,
generated 19 signals (21.6%) from 88 water negative controls. The
XMRV/pMLV amplifications produced 15 signals (17%) and the
Figure 1. Agarose gel analysis of R2 from experiment 1. gag
nested PCR for 80 cDNAs derived from blood donors and controls.
Lanes 1A–1H ten fold dilution series of XMRV TCS (Lane 1A equivalent
to 5.5610
6 to 5.5610
21 cDNA molecules/PCR – determined by Poisson
distribution). Lanes 2A–11H 80 cDNAs derived from blood donor whole
blood. Lanes 12A–12H ten fold dilution series of Balb/c DNA 10
5 pg to
0.10 pg, negative.
doi:10.1371/journal.pone.0019953.g001
Table 2. Details of sequences obtained.
Experiment/Source
material
Sequence
Identity/
and size Class
gag Homology %
to XMRV
VP62_DQ399707
gag
Homology %
to CFS1
(pMLV
M630562)
Most
homologous Homology %
Source M. musculus
unless stated
1/WB cDNA 7C, 372 bp Modified
polytropic
(96.8%) (98.4%) AC153369 99.7/372 bp 10 BAC RP23-103E4
1/WB cDNA 9C, 311 bp Xenotropic 307/374 (82.1%) 300/374
(80.2%)
FB579941 98.3/176 bp XMRV Patent
WO2006110589
2/Water 2D, 373 bp Polytropic 360/373 (96.5%) 365/373
(97.9%)
AC184103.1 99.7/373 bp chromosome Y M.
spretus BAC clone
CH35-73N5
2/Water 3F,352 bp Xenotropic- 345/373 (92.5%) 335/373
(89.8%)
M26006 100/352 bp endogenous retrovirus
truncated gag gene,
clone del env-2 15.3
2/Water 7H, 373 bp Polytropic 358/373 (96.0%) 363/373
(97.3%)
AC093923.3 100/373 bp RP23-174H21
2/Water 12C, 373 bp Modified
polytropic
362/373 (97.1%) 368/373
(98.7%)
AC127319.4 100/373 bp chromosome 5 BAC
clone RP23-229N3
2/Water 12D, 373 bp Polytropic 358/373 (96.0%) 363/373
(97.3%)
CR954969.10 100/373 bp chromosome X clone
RP23-332J14
3/WB cDNA 7Cpol, 168 bp N/A N/A N/A AC117614.14 100/168 bp chromosome 5, clone
RP23-110C17
WB=Whole Blood.
doi:10.1371/journal.pone.0019953.t002
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The Ct’s were late for all these reactions, between 37.8 and 46.0
for the XMRV/pMLV and 37.8 and 39.3 with the IAP-D1 Q-
PCR; equivalent to 0.1 pg or less of murine DNA per reaction.
These 19 amplifications each occurred independently, there were
no co-amplification dual positives, these frequencies are consistent
with the presence of a single target molecule per reaction.
The results of the sequence alignments are shown as a
phylogenetic tree (Figure 2) and confirm those obtained in FASTA
searches. Sequences 12D, 2D and 7H fall within the pMLVs
whereas 7C and 12C are mpMLVs. 3F and 9C cluster with
xenotropic MLVs and XMRV. Interestingly 9C carried the same
deletion as MLV001 (HQ601957), which was amplified from a
patient with CFS.
Discussion
The gag sequences described (Table 2) should be detectable by
our modified Taq Man assay with the possible exception of one, a
xenotropic sequence (3F) that carried a T to A change four bases
in from the 39 end of the forward primer. The confirmed existence
of murine sequences in the IPT enzyme underline real concerns
over the source of similar reported sequences. The higher
detection rate in the TaqMan assay, 15 positives against the
initial finding of 4 by nested PCR is what one would expect as the
TaqMan sequence amplified is smaller. If these ‘‘positives’’ were
sample derived the absence of a signal from the murine detector
channel (IAP) would have led them to be mistakenly considered
real. However, our interpretation is that the lack of concordant
positives is because very low levels of DNA were present, that it is
probably very fragmented and that small volumes will not
necessarily contain both targets. These findings suggest that
probing for murine genomic DNA, for example using IAP PCR,
although advisable to identify overt murine DNA contamination,
may not always be sufficient to exclude very low copy contaminant
sequences.
XMRV research is a contentious field with controversy over
both the discrepant findings of different groups and the reasons
behind this. Contamination has been suggested as a problem, from
sequences contained in positive samples, amplified products and
plasmids. To this, it is now appropriate to add the presence of
murine material either in the general laboratory environment, in
Figure 2. Maximum likelihood tree of gag sequences. The MLV RAxML tree for gag sequences lying between XMRV primers gagIF and gagIR
was developed from the endogenous MLV sequences identified by Jern et al [19], sequences derived from CFS patients by Lo et al [5] (shown in red
and blue) and the sequences amplified in this study (in green). In addition to sequences from the RNA and DNA, ‘‘1F_131010’’ and ‘‘1F’’ are included.
1F_131010 was derived from the amplification of cDNA synthesized from RNA extracted from the tissue culture fluid supernatant of an XMRV culture,
kindly provided by Professor M McClure. 1F was derived from the amplification of Balb/c mouse DNA (Sigma). Bootstrap values .50 are indicated.
doi:10.1371/journal.pone.0019953.g002
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used to detect XMRV/pMLV sequences. Robinson and col-
leagues have just demonstrated that murine sequences can be
present in prostate sections and give false positives when searching
for XMRV [21]. A study of XMRV in patients with CFS or
chronic immunomodulatory conditions, using IPT reported a gag
sequence with .99% homology to a mouse endogenous retrovirus
[22]. This was designated as contamination although the source of
this sequence was not speculated. Sato and colleagues recently
reported finding sequences, predominantly RNA, related to a
pMLV in IPT containing reagents [23]. Another study just
published, concluded that the detection of MLV-related sequences
in human samples could be due to contamination with mouse
DNA, most likely contained in various laboratory reagents [24].
Finally, a phylogenetic overview concluded that the proviral
sequences present in the genome of 22Rv1 cell line were ancestral
to the published XMRV sequences [25].
Our data was similar to that of Oakes and colleagues in that a
variety of MLV sequences were detected, however, our results
were not related to the sample input which in our case were water
replicates. Similarly, Sato and colleagues had found sequences
derived from Invitrogen RT-PCR reagents, however they found a
single pMLV rather than a variety of MLV sequences as Oakes
and ourselves describe.
The exact variety and nature of our sequences show very close
parallels to those reported by Lo and colleagues from patients
with CFS [5] especially in the set of samples from recent repeat
isolations. They argue that the recent sequences (MLV001–
MLV006; HQ601957–62) show evidence of viral evolution from
an earlier sequence (assumed here to be cfs1 since this was
identified in 18/21 sequences). However such evolution would be
predicted to show monophylogeny. Our maximum likelihood
analysis of these sequences is clearly inconsistent with such a
prediction (Figure 2). In particular we see no obvious explanation
for a sequence of the modified polytropic cfs1 type evolving into a
polytropic sequence like MLV002 or MLV006 (Figure 3),
Similarly it seems implausible that MLV001, which shares with
9C a deletion encoding 15 amino acids of matrix (MA),
presumably precluding virus replication, could evolve from cfs1.
In the absence of evidence for replication competent MLV in the
samples reported by Lo and colleagues, we believe that the
finding of a population of gag sequences in the reagents, as well as
the coincidence of a virtually identical replication incompetent
MLV in our study and that of Lo and colleagues, must call into
question the biological provenance of these sequences and
therefore any conclusions drawn [5] concerning their relationship
to CFS.
We found that contamination can be sporadic and so not
immediately apparent. Although with one manufacturer’s kit
virtually all water controls gave amplification (Qiagen QuantiTect
Virus Kit), the contamination described in this study with IPT
reagents only became apparent once a large number of known
negative samples (water) were amplified. This contamination of
the Taq reagents with murine DNA sequences may be due to the
enzyme mix itself and a consequence of the hot start mechanism.
IPT has a mouse monoclonal antibody blocking the active site
which is heat denatured for activation. This could contain murine
DNA, potentially in variable amounts in different lots.
We do not believe that our observations serve to indicate that
XMRV/pMLV sequences detected ex vivo in human materials
inevitably will have come from the amplification reagents. Nor for
that matter can we explain how in some studies there have been
very significant differences between the detection rates in cases and
comparator groups.
Figure 3. Alignment between cfs1, MLV006, Pmv15 and Pmv22. The nine nucleotide differences between cfs1 and the other viral sequences
are highlighted.
doi:10.1371/journal.pone.0019953.g003
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XMRV in multiple ways depending on the source of the
adventitious nucleic acid. Presence of material (RNA or DNA)
from 22Rv1 cells would result in sequences identical or nearly
identical to XMRV. Alternatively, mouse DNA could be the
problem in other studies, when a variety of endogenous MLV will
be amplified resulting in a range of related sequences as seen in
this study. In particular we caution that the reagents used to detect
MLV-like sequences may themselves have been contaminated
with murine DNA. Although we do not suggest that this is the
primary source of the XMRV/pMLV sequences observed in
previous studies, it could well represent a confounding factor and
note that the original detection of XMRV gag sequences by
Urisman and colleagues used Invitrogen Taq and Lo and
colleagues used IPT reagents. Finally we believe we would be
wise to remember the classical warning ‘‘Caveat Emptor’’.
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